FibroBiologics, Inc. FBLG
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -12.00% | -9.36% | 0.09% | 14.21% | 22.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.00% | 15.97% | 21.19% | 42.10% | 43.54% |
| Operating Income | -4.00% | -15.97% | -21.19% | -42.10% | -43.54% |
| Income Before Tax | -37.18% | -143.64% | -67.06% | -4.06% | 32.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.18% | -143.64% | -67.06% | -4.06% | 32.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.18% | -143.64% | -67.06% | -4.06% | 32.09% |
| EBIT | -4.00% | -15.97% | -21.19% | -42.10% | -43.54% |
| EBITDA | -3.64% | -15.60% | -20.79% | -41.90% | -43.26% |
| EPS Basic | 20.62% | -75.43% | -26.86% | 20.30% | 45.70% |
| Normalized Basic EPS | 20.62% | -75.42% | -26.86% | 20.30% | 45.70% |
| EPS Diluted | 20.62% | -75.43% | -26.86% | 20.30% | 45.70% |
| Normalized Diluted EPS | 20.62% | -75.42% | -26.86% | 20.30% | 45.70% |
| Average Basic Shares Outstanding | 112.77% | 58.60% | 35.79% | 21.43% | 18.82% |
| Average Diluted Shares Outstanding | 112.77% | 58.60% | 35.79% | 21.43% | 18.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |